Hyloris Pharmaceuticals Valuation

Is 52U undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 52U when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate 52U's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate 52U's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 52U?

Key metric: As 52U is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for 52U. This is calculated by dividing 52U's market cap by their current revenue.
What is 52U's PS Ratio?
PS Ratio	23.2x
Sales	€6.94m
Market Cap	€160.72m

52U key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	19.4x
Enterprise Value/EBITDA	-10x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does 52U's PS Ratio compare to its peers?

The above table shows the PS ratio for 52U vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	5x
PSG PharmaSGP Holding	2.6x	7.7%	€280.6m
2FJ0 Pierrel	3.4x	n/a	€92.8m
93M1 MPH Health Care	0.9x	-60.2%	€105.3m
0RX Redx Pharma	13.3x	-37.6%	€65.0m
52U Hyloris Pharmaceuticals	23.2x	70.3%	€160.7m

Price-To-Sales vs Peers: 52U is expensive based on its Price-To-Sales Ratio (23.2x) compared to the peer average (5x).

Price to Sales Ratio vs Industry

How does 52U's PS Ratio compare vs other companies in the European Pharmaceuticals Industry?

23 Companies	Price / Sales	Estimated Growth	Market Cap

23 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Sales vs Industry: 52U is expensive based on its Price-To-Sales Ratio (23.2x) compared to the European Pharmaceuticals industry average (2.9x).

Price to Sales Ratio vs Fair Ratio

What is 52U's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

52U PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	23.2x
Fair PS Ratio	24.4x

Price-To-Sales vs Fair Ratio: 52U is good value based on its Price-To-Sales Ratio (23.2x) compared to the estimated Fair Price-To-Sales Ratio (24.4x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 52U forecast and predictions for the stock price in 12 month’s time.
Date	Share Price	Average 1Y Price Target	Dispersion	High	Low	1Y Actual price	Analysts
Current	€5.66	€11.10 +96.1%	55.0%	€17.20	€5.00	n/a	2
Nov ’25	€5.56	€11.10 +99.6%	55.0%	€17.20	€5.00	n/a	2
Oct ’25	€5.76	€11.10 +92.7%	55.0%	€17.20	€5.00	n/a	2
Sep ’25	€5.72	€11.10 +94.1%	55.0%	€17.20	€5.00	n/a	2
Aug ’25	n/a	€19.10 0%	9.9%	€21.00	€17.20	n/a	2
Jul ’25	n/a	€21.55 0%	2.6%	€22.10	€21.00	n/a	2
Jun ’25	n/a	€21.55 0%	2.6%	€22.10	€21.00	n/a	2
May ’25	€11.40	€21.55 +89.0%	2.6%	€22.10	€21.00	n/a	2
Apr ’25	€10.80	€20.65 +91.2%	1.7%	€21.00	€20.30	n/a	2
Mar ’25	€12.00	€19.90 +65.8%	2.0%	€20.30	€19.50	n/a	2
Feb ’25	€12.95	€19.90 +53.7%	2.0%	€20.30	€19.50	n/a	2
Jan ’25	€12.50	€19.90 +59.2%	2.0%	€20.30	€19.50	n/a	2
Dec ’24	€12.30	€19.90 +61.8%	2.0%	€20.30	€19.50	n/a	2
Nov ’24	€12.20	€19.90 +63.1%	2.0%	€20.30	€19.50	€5.56	2
Oct ’24	€11.60	€19.25 +65.9%	1.3%	€19.50	€19.00	€5.76	2
Jul ’24	€10.90	€19.75 +81.2%	1.3%	€20.00	€19.50	n/a	2

Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.

Discover undervalued companies

Aspen Pharmacare Holdings

R75.5b

Manufactures and supplies specialty and branded pharmaceutical products worldwide.

LDZA

R8.95

0.6%

4.7%

Amneal Pharmaceuticals

US$2.6b

Develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide.

2DT

US$7.70

-4.3%

91.5%

Collegium Pharmaceutical

US$966.2m

A specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management.

354

US$29.00

5.1%

22.9%